The role of megsin, a serine protease inhibitor, in diabetic mesangial matrix accumulation  by Ohtomo, Shuichi et al.
The role of megsin, a serine protease inhibitor, in
diabetic mesangial matrix accumulation
Shuichi Ohtomo1, Masaomi Nangaku2, Yuko Izuhara1, Norio Yamada3, Takashi Dan3, Takefumi Mori4,
Sadayoshi Ito4, Charles van Ypersele de Strihou5 and Toshio Miyata3
1Institute of Medical Sciences, Tokai University, Kanagawa, Japan; 2Division of Nephrology and Endocrinology, University of Tokyo
School of Medicine, Tokyo, Japan; 3Center for Translational and Advanced Research, Tohoku University Graduate School of Medicine,
Sendai, Japan; 4Division of Nephrology Endocrinology and Vascular Medicine, Tohoku University School of Medicine, Sendai, Japan and
5Service de Nephrologie, Universite Catholique de Louvain, Brussels, Belgium
In diabetic nephropathy decreased activities of matrix
metalloproteinase (MMP)-2, MMP-9 and plasmin contribute
to mesangial matrix accumulation. Megsin, a novel member
of the serine protease inhibitor superfamily, is predominantly
expressed in mesangial cells and is up-regulated in diabetic
nephropathy and its overexpression spontaneously induces
progressive mesangial expansion in mice. High-glucose
stimulated megsin mRNA expression in an in vivo model of
type II diabetic nephropathy as well as in vitro in cultured
mesangial cells. Megsin potentially inhibits total enzymatic
activities of MMP-2 and -9 and plasmin, indicating decreased
degradation of mesangial matrix. A specific monoclonal
anti-megsin neutralizing antibody restored MMP activity
in a transforming growth factor-b independent manner.
Our study suggests that the mesangial matrix accumulation
caused by hyperglycemia in diabetes might be due at least
in part to up-regulation of megsin which can inhibit plasmin
and MMP activities.
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Diabetic nephropathy is characterized by a progressive
mesangial expansion mainly due to the accumulation in the
extracellular matrix (ECM) of collagen IV, laminin, fibro-
nectin, proteoglycans, and other matrix proteins.1–6 This
accumulation is due to a disturbed balance between synthetic
and degradative pathways.2,3
Two major proteolytic pathways degrade glomerular ECM,
namely, matrix metalloproteinases (MMPs) and plasmin.
MMP-2 and MMP-9 cleave collagen IV, laminin, and
fibronectin, and the serine protease plasmin degrades laminin
and fibronectin.7–9 MMP-2 and MMP-9 are synthesized
in latent forms, unable to effect proteolysis.10,11 Plasmin
also converts inactive into active MMPs.10,12,13 It is now
recognized that in diabetic nephropathy, glomerular ECM
accumulation is mediated by a plasmin/MMPs cascade,
that is, decreased activities of plasmin and MMP-2 and
MMP-9.7–10,14
To elucidate the pathogenesis of diabetic kidney disease, a
functional quantitative analysis of the genome in cultured
human mesangial cells was performed and the expression
levels of a variety of mesangial transcripts with those
observed in other non-renal cells were compared.15
Megsin, a novel member of the serine protease inhibitor
(serpin) superfamily, is predominantly expressed in mesan-
gial cells.16 By in situ hybridization and immunohistochem-
istry, megsin gene and proteins were mesangial cells.16–18 Its
overexpression in transgenic mice induces progressive
mesangial matrix accumulation.19 Although its expression
is ubiquitous, its pathogenic effects are restricted to
glomeruli. Cross-breeding of this mouse model with RAGE
(the receptor for advanced glycation end products)/inducible
nitric oxide synthase double transgenic diabetic mice has a
triple transgenic model characterized by a severe mesangial
matrix accumulation, including nodular lesions, similar to
those observed in humans.20
In the present study, we used a neutralizing antibody
against megsin activity to investigate the role of megsin in the
glomerular ECM accumulation characteristic of diabetic
nephropathy. In vitro and in vivo data demonstrate that
hyperglycemia upregulates megsin, which, in turn, inhibits
o r i g i n a l a r t i c l e http://www.kidney-international.org
& 2008 International Society of Nephrology
Received 5 February 2008; revised 27 March 2008; accepted 23 April
2008; published online 25 June 2008
Correspondence: Toshio Miyata, Center for Translational and Advanced
Research, Tohoku University Graduate School of Medicine, 2-1 Seiryo-Machi,
Aoba-ku, Sendai, Miyagi 980-8575, Japan.
E-mail: t-miyata@mail.tains.tohoku.ac.jp
768 Kidney International (2008) 74, 768–774
plasmin and MMPs in a transforming growth factor (TGF)-
b-independent manner. This chain of events potentially
contributes to ECM accumulation in diabetic glomeruli.
RESULTS
Megsin expression in diabetic SHR/NDmcr-cp rats
Spontaneously hypertensive/NIH-corpulent (SHR/NDmcr-cp)
rats are a well-known type II diabetic rat model.21 At the age
of 17 weeks, SHR/NDmcr-cp rats exhibited a wide range of
metabolic abnormalities, that is, hyperglycemia, dyslipide-
mia, and hypertension (Table 1) in comparison with control
Wistar-Kyoto (WKY) rats. A real-time PCR analysis in the
renal cortex revealed a significant increase in the megsin
mRNA expression in diabetic SHR/NDmcr-cp rats, com-
pared with WKY rats (Po0.01, Figure 1a).
To ascertain the metabolic factors involved in the
upregulation of megsin expression, we assessed megsin
expression in diabetic SHR/NDmcr-cp rats treated with
several drugs, that is, insulin, olmesartan, and bezafibrate.
The biological data of experimental animals at the end of the
study (aged 39 weeks) are summarized in Table 2. All drugs
significantly reduced total cholesterol and triglycerides levels
at the end of study. Insulin, but not other agents, significantly
improved hyperglycemia, whereas only olmesartan achieved a
better blood pressure control. The increase in megsin
expression observed in SHR/NDmcr-cp rats was significantly
lowered only by insulin treatment (Po0.05, Figure 1b).
These findings suggest that hyperglycemia, but not hyperten-
sion and hyperlipidemia, is associated with the upregulation
of megsin expression.
Megsin expression in vitro in RMCs
We next examined whether high glucose induces megsin
expression in vitro in cultured rat mesangial cells (RMCs). As
expected from the in vivo results, megsin mRNA expression
was significantly increased in RMCs cultured in high glucose,
compared with low glucose (Po0.05, Figure 2). High
osmolarity did not affect megsin expression.
Effects of megsin on plasmin and MMP activities in vitro
Megsin inhibits an enzymatic activity of plasmin, a well-
known enzyme that converts inactive into active MMPs.10,19
We thus tested the interrelation between megsin and MMP
activities in vitro in RMCs. Incubation for 72 h in a megsin-
fortified medium significantly decreased not only plasmin
activity (Figure 3a, Po0.001) but also total MMP-2 and
MMP-9 activities (Figure 3b, Po0.05).
We also tested a direct interrelation between megsin and
MMP activities. In cell-free assay system, megsin did not
affect MMPs activity (1.00±0.02 of MMP vs 0.98±0.01 of
MMP and megsin). These data thus suggest that megsin
indirectly links to MMP activation via the inhibition of
plasmin enzymatic activity.
Characterization of anti-megsin monoclonal antibody MS18a
To understand the role played by endogenous megsin, an
anti-megsin monoclonal antibody named MS18a was devel-
oped. Epitope mapping analysis showed that the anti-megsin
antibody MS18a was directed against the residues NIVEKQ
located in the reactive loop site of human megsin protein16
(Table 3). The residues NIVEKL in rat megsin protein
correspond to the residues NIVEKQ in the human megsin
Table 1 | Biochemical and physiological data of the
experimental rats aged 17 weeks
WKY DM
HbA1c (%) 3.0±0.1 6.8±0.3***
Total cholesterol (mg per 100 ml) 141±3 163±4**
Triglyceride (mg per 100 ml) 81±13 720±61***
Systolic blood pressure (mm Hg) 129±2 165±4***
WKY, Wistar-Kyoto.
**Po0.01, ***Po0.001 vs WKY. Data are represented as the mean±s.e.m.
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Figure 1 | Upregulation of megsin mRNA expression in
diabetic rat kidney. (a) Megsin mRNA expression in kidney
tissues at the age of 17 weeks in diabetic SHR/NDmcr-cp rats (DM)
and control WKY rats (WKY). (b) Megsin mRNA expression at age
the of 39 weeks in diabetic SHR/NDmcr-cp rats (DM), DM rats
on insulin (DMþ ins), rats on olmesartan (DMþ olme), rats on
bezafibrate (DMþbeza), and control WKY rats (WKY). The mRNA
expression of megsin was highly upregulated in diabetic kidneys,
and was significantly decreased only by insulin treatment.
*Po0.05, **Po0.01 vs WKY; wPo0.05 vs DM.
Table 2 | Biochemical and physiological data of the experimental rats aged 39 weeks
WKY DM DM+ins DM+olme DM+beza
HbA1c (%) 3.3±0.0 5.3±0.3*** 3.3±0.2www 5.3±0.2*** 5.2±0.3***
Total cholesterol (mg per 100 ml) 128±3 186±10*** 132±8www 141±5www 132±7www
Triglyceride (mg per 100 ml) 39±2 407±44*** 221±42**,ww 259±30***,w 239±23***,ww
Systolic blood pressure (mm Hg) 139±3 170±4** 178±6*** 115±6*,www 173±4***
WKY, Wistar-Kyoto.
*Po0.05, **Po0.01, ***Po0.001 vs WKY; wPo0.05, wwPo0.01, wwwPo0.001 vs DM. Data are represented as the mean±s.e.m.
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reactive loop site.22 We confirmed that MS18a was also
directed against rat megsin peptide containing NIVEKL
residues (bottom of Table 3). These data suggest that the
epitope of MS18a is the residues NIVEKQ/NIVEKL.
We further validated the neutralizing activity of anti-
megsin monoclonal antibody MS18a using cell-free assay
system. The reduction of plasmin activity by human megsin
protein was increased by anti-megsin antibody MS18a
(Po0.001), in contrast to control IgG (Figure 4). The
blocking peptide corresponding to the reactive loop site of rat
megsin competitively reduced plasmin activity restored by
MS18a, which was found to be significant (Po0.001). These
findings revealed that MS18a has the potential to neutralize
not only human but also rat megsin enzymatic activity
against plasmin.
Role of megsin in RMCs under high-glucose condition
To elucidate the role of high-glucose-induced megsin, we
investigated MMPs activities in vitro in RMCs using anti-
megsin monoclonal neutralizing antibody MS18a. As shown
in Figure 3, megsin mRNA expression was upregulated under
high-glucose conditions. The total MMP-2 and MMP-9
activities were significantly decreased in RMCs cultured in a
high-glucose medium, compared with low-glucose (Po0.05,
Figure 5). MS18a significantly (Po0.01) increased total
MMP-2 and MMP-9 activities in RMCs cultured in a high-
glucose medium, in contrast to control IgG. We also
confirmed, in cell-free direct assay system, that MS18a did
not affect MMP activity directly (1.00±0.01 of MMP vs
1.02±0.02 of MMP and MS18a). These findings suggest that
hyperglycemic conditions reduce MMP activities, at least in
part, through the megsin modulation.
Relationship between megsin and TGF-b
TGF-b is a pivotal factor in the development of glomerular
ECM accumulation in diabetic nephropathy.3,10,23 The
interrelation between TGF-b and megsin was therefore
evaluated. TGF-b did not affect the mRNA expression of
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Figure 2 | Megsin expression in vitro in rat mesangial cells
(RMCs). Cells were exposed to 5 mM glucose (LG), 25 mM glucose
(HG), or 5 mM glucoseþ 20 mM mannitol (LGþmannitol) for 72 h.
Megsin mRNA expression was significantly higher in RMCs
cultured in a high-glucose medium. *Po0.05 vs LG.
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Figure 3 | Effects of megsin on plasmin and MMPs activities.
(a) The activity of plasmin, and (b) total MMP-2 and MMP-9
activities in RMCs cultured in a megsin-fortified medium
(low-glucose). Megsin significantly decreased the plasmin activity,
and the total MMP-2 and MMP-9 activities. *Po0.05, ***Po0.001
vs control.
Table 3 | Epitope mapping of anti-megsin monoclonal
antibody MS18a
Peptide sequence MS18a antibody activity
TAATGSNIVEKQLPQST 
AATGSNIVEKQLPQST 
ATGSNIVEKQLPQST 
TGSNIVEKQLPQST 
GSNIVEKQLPQST 
SNIVEKQLPQST 
NIVEKQLPQST 
IVEKQLPQST +
VEKQLPQST ++
TAATGSNIVE ++
TAATGSNIVEK ++
TAATGSNIVEKQ 
TAATGSNIVEKQL 
TAATGSNIVEKQLP 
TAATGSNIVEKQLPQ 
TAATGSNIVEKQLPQS 
NIVEKQ 
TAATESNIVEKLLPES 
++, antibody activity similar to non-peptide control; +, about half of antibody
activity; , complete loss of antibody activity.
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Figure 4 | Characterization of anti-megsin monoclonal
antibody MS18a. Cell-free assay for validation of neutralizing
activity of MS18a. BP, blocking peptide, corresponding to the rat
megsin reactive loop site. MS18a significantly neutralized megsin
enzymatic activity against plasmin. **Po0.01, ***Po0.001 vs
plasmin only (far left); wwPo0.01, wwwPo0.001 vs plasmin and
megsin (second left); zzzPo0.001 vs MS18a (second right).
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megsin in RMCs, in contrast to plasminogen activator
inhibitor (PAI)-1 and connective tissue growth factor, both
well known TGF-b-induced genes24,25 (Figure 6a). PAI-1
itself plays an important role in glomerular ECM accumula-
tion as well as TGF-b.26
Megsin did not affect the mRNA expressions of TGF-b
and PAI-1 (Figure 6b), and did not modify the enzymatic
activity of PAI-1 (1.00±0.02 of PAI-1 vs 1.04±0.01 of PAI-1
and megsin). These findings suggest that the expression of
megsin is independent of the production of TGF-b and PAI-1.
DISCUSSION
Megsin is implicated in the development of renal diseases,
including diabetic nephropathy, but its biological function
remains elusive. Using binding and functional assays in vitro,
we previously reported that megsin is a proteinase inhibitor
whose biological substrate is plasmin.19 We also observed the
upregulation of megsin in human diabetic nephropathy.16,27
In the present study, we now demonstrate that high glucose
per se induces megsin expression both in vivo in a model of
type II diabetic nephropathy and in vitro in cultured
mesangial cells in which it also inhibits total MMP-2 and
MMP-9 activities and plasmin enzymatic activity. These data
suggest that the reduction of protease activities decreases the
degradation of glomerular ECM and results in mesangial
expansion in diabetic nephropathy. This is consistent with
the aggravation of diabetic nephropathy with Kimmelstiel–-
Wilson-like nodules in the triple transgenic mice over-
expressing inducible nitric oxide synthase, RAGE, and
megsin.20 The current study clarifies, at the molecular level,
the pathophysiogical role of megsin upregulation in diabetic
nephropathy.
Previously, we demonstrated that the activator protein
(AP)-1 binding site is within the 50-flanking region of megsin
gene and that it potentially regulates megsin expression.28
The transcription factor AP-1 regulates various gene expres-
sions through its binding site. AP-1 binding increases in
mesangial cells under hyperglycemic conditions.29 Hence,
megsin is upregulated under hyperglycemic conditions
through increased AP-1 binding. The upregulation of megsin
is due to a metabolic effect of high glucose, as osmolarity
control with mannitol failed to induce megsin expression in
our experiments. However, glucose level is not the sole
regulator of megsin expression. Megsin is upregulated not
only in diabetic conditions but also in non-diabetic
glomerulonephritis, that is, IgA nephropathy.16,17 The
mechanism underlying the upregulation of megsin in IgA
nephropathy remains elusive, and requires further studies to
elucidate its molecular mechanisms.
Under normal circumstances, MMP activities are tightly
regulated.10 Our in vitro studies with the anti-megsin
neutralizing antibody demonstrated that megsin decreased
the active forms of MMP-2 and MMP-9 under hyperglycemic
conditions via the inhibition of plasmin enzymatic activity.
This decrease plays a role in glomerular ECM overaccumula-
tion, which resulted in diabetic glomerulosclerosis.7–10,14,30,31
Indeed, angiotensin-converting enzyme inhibitors, statins,
and estradiol, restore the reduced activities of MMPs and
provide renoprotection.32–35 Under hyperglycemic condi-
tions, however, the suppression of MMPs activity was partial
in contrast to the drastic upregulation of megsin, suggesting
that factors other than megsin also contribute to this effect.
All serpins including megsin share a common structure,
that is,36 a b-sheet-rich body and an exposed mobile reactive
loop, which functions as a pseudosubstrate for the target
protease (for example, plasmin for megsin). The inhibitory
mechanism of serpin rests on the unique conformational
flexibility, and the insertion of the cleaved reactive center
loop of the serpin into the large central b-sheet, leading to the
formation of a stable proteinase–serpin complex. Our in vitro
studies demonstrate that MS18a specifically recognized
the residues NIVEKQ/NIVEKL, comprised in the reactive
loop site of human, chimpanzee (XP_524011.2), dog
(XP_541072.2), rat, and mouse megsin.16,22 It thus restores
the access of plasmin to cleave the reactive center loop of
megsin. Neutralizing antibodies against PAI-1, another
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Figure 5 | Role of megsin in mesangial cells under
high-glucose condition. RMCs were exposed to 5 mM glucose
(LG), 25 mM glucose (HG), HG with anti-megsin neutralizing
antibody MS18a, or HG with control IgG for 72 h. Lowered total
MMP-2 and MMP-9 activities in HG were significantly increased
via neutralizing of megsin activity by MS18a. *Po0.05 vs LG,
wwPo0.01 vs HG.
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Figure 6 | Correlation between megsin and TGF-b. (a) Effects
of TGF-beta on genes expressions of megsin, PAI-1, and
connective tissue growth factor (CTGF), and (b) the effect of
megsin on TGF-b and PAI-1 in RMCs cultured in low-glucose
(LG) medium. There is no correlation between megsin and TGF-b.
**Po0.01, ***Po0.001 vs LG control.
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member of the serpin superfamily, also recognize the
corresponding portion of the reactive loop site.37
TGF-b plays a pivotal role in the ECM accumulation in
diabetic glomeruli.3,10,23 It controls MMP activities by
modulating transcription; by post-translational modification,
that is, the inhibition of plasmin generation via PAI-1; and by
the upregulation of tissue inhibitors of metalloproteinases-
1.3,10,23,24,38 The mechanism of the inhibition of MMP
activities by megsin is independent of TGF-b, in contrast to
the protective mechanism of PAI-1 deficiency in a model
of diabetic nephropathy, which appears to be mediated by
TGF-b.39 A hypothetical schema depicted in Figure 7
tentatively integrate these various observations to understand
the genesis of diabetic glomerular lesions. The inhibition of
MMP activities by megsin and TGF-b are independent from
each other, so that megsin could become a novel therapeutic
target to prevent diabetic glomerular ECM accumulation.
The future availability of megsin inhibitors should also open
new therapeutic avenues.
In conclusion, high glucose induces the upregulation of
megsin both in vitro and in vivo. Functional studies show that
megsin inhibits the activities of plasmin and MMPs indepen-
dent of TGF-b. The upregulation of megsin thus links to
pathological changes in diabetic nephropathy. The current
study clarifies, for the first time, at the molecular level, the role
of megsin upregulation in diabetic nephropathy.
MATERIALS AND METHODS
Type II diabetic rats
All animal experiments were performed in accordance with the
guidelines of the Committee on Ethical Animal Care and Use of
Tokai University.
Ten male SHR/NDmcr-cp rats and five WKY rats were purchased
from SLC (Shizuoka, Japan). They were housed in individual cages
under a temperature- and light-controlled environment in an
accredited animal care. At the end of the study, at the age of
17 weeks, they were killed and blood samples were obtained.
Separately from the above experiment, a total of 39 male
SHR/NDmcr-cp rats and 10 WKY rats were purchased from SLC.
SHR/NDmcr-cp rats, aged 13 weeks, were randomly divided into
four groups, namely, Group 1 received vehicle orally (DM, n¼ 10),
Group 2 received insulin subcutaneously (30 units/kg, twice a day)
(DMþ ins, n¼ 9), Group 3 received olmesartan orally (5 mg/kg)
(DMþolme, n¼ 10), and Group 4 received bezafibrate orally
(25 mg/kg) (DMþ beza, n¼ 10). WKY rats served as a control
group (WKY, n¼ 10). The drug treatment lasted for 26 weeks. At
the end of the study, at the age of 39 weeks, they were killed and
blood samples were obtained.
The following methods were used: HbA1c by the DCA2000
(Bayer Diagnostics, Pittsburgh, PA, USA), plasma total cholesterol
and triglycerides by the automatic analyzer (Hitachi Automatic
Clinical Analyzer 7170, Hitachi Science Systems, Ibaraki, Japan), and
systolic blood pressure in conscious rats by the tail-cuff method.
Total RNA was extracted from renal cortex tissues for gene
expression analysis with the RNeasy Mini Kit (Qiagen GmbH,
Hilden, Germany) according to the manufacturer’s instructions.
Gene expression analysis
Real-time PCR was performed by a previously described method40
with the One Step RT-PCR Kit (Takara Bio Inc., Shiga, Japan), SYBR
Green I reagent (Cambrex Bio Science, Rockland, ME, USA), and
iCycler PCR system (Bio-Rad Laboratories, Hercules, CA, USA) for
the evaluation of the mRNA expression of megsin, TGF-b, PAI-1,
connective tissue growth factor, and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH). Primer sequences are listed in Table 4.
GAPDH mRNA expression was used for the normalization of these
genes expressions. Data are presented as relative values.
Culture of RMCs
RMCs, a cultured cell line originating from mesangial cells of male
Sprague–Dawley rats, were purchased from ATCC (Manassas, VA,
USA). For the present experiments, cells obtained after 10 and 12
passages were used. RMCs were cultured in Dulbecco’s Modified
Eagle’s Medium (DMEM) (Invitrogen, Carlsbad, CA, USA)
supplemented with 10% fetal bovine serum and 0.4 mg/ml G-418.
Megsin expression in RMCs
RMCs were maintained in DMEM containing either 5 or 25 mM
D-glucose with 10% fetal bovine serum for 72 h (n¼ 6). The effect of
hyperosmolality was assessed in RMCs cultured in DMEM contain-
ing 5 mM D-glucose supplemented with 20 mM mannitol. For gene
expression analysis, total RNA was isolated from RMCs with the
RNeasy Mini Kit according to the manufacturer’s instructions.
Table 4 | Primers for real-time PCR
Gene Forward primer (50–30) Reverse primer (50–30)
Megsin AGAATTTGGCTTCGACTTATTCAGAGAGATGG ATGACAGCTGATGAGCTGAGGCTGCTGTCCCCC
TGF-b TGCGCCTGCAGAGATTCAAG AGGTAACGCCAGGAATTGTTGCTA
PAI-1 GCCCAGCATTCAGCCTTTG AAGACTTTGCTGAGTGAAGGCGTAG
CTGF CACCCGGGTTACCAATGACAA AGCCCGGTAGGTCTTCACACTG
GAPDH GACAACTTTGGCATCGTGGA ATGCAGGGATGATGTTCTGG
CTGF, connective tissue growth factor; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; TGF-b, transforming growth factor-b.
Hyperglycemia
Mesangial expression
Megsin
MMPs expression
MMPs activity
TGF-β
PAI-1
TIMP-1
Plasmin generationPlasmin activity
ECM degradation
Figure 7 | Hypothetical schema for diabetic glomerular ECM
accumulation. Megsin is a potent suppressor of glomerular MMP
activities in diabetes, independently of TGF-b.
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Recombinant human megsin protein
The entire coding sequence of human megsin cDNA was ligated into
the His-tag fusion protein vector pET28a (Novagen Inc., Madison,
WI, USA). The His-tagged megsin protein was expressed in
Escherichia coli, and affinity purified by Ni Sepharose 6 Fast Flow
(GE Healthcare UK Ltd., Buckinghamshire, UK) according to the
manufacturer’s instructions.
Effects of megsin on plasmin and MMP activities in RMCs
RMCs were cultured in 96-well plates and grown to subconfluence.
They were subsequently washed and incubated with serum-starved
DMEM (5 mM D-glucose) containing 0.05 U/ml plasminogen
(Sigma-Aldrich Inc., St Louis, MO, USA) with or without
recombinant human megsin (100 mg/ml) for 72 h (n¼ 6). After
incubation, culture supernatant was collected for the measurement
of the activities of plasmin and gelatinases (total activities of MMP-2
and MMP-9). This experimental system, that is, activation of MMPs
in cultured mesangial cells by exogenous plasminogen addition, has
been previously reported.23,38
Measurement of MMP and plasmin activities
Plasmin activity in medium obtained from RMCs was determined as
below. 50 ml of each medium sample were incubated with 0.3 mM of
a plasmin colorimetric substrate, S-2403 (Daiichi Pure Chemicals,
Co., Ltd., Tokyo, Japan) for 60 min, and absorbance was measured
at 405 nm. The total MMP-2 and MMP-9 activities (gelatinase
activity) in medium from RMCs were determined by a commercially
available kit LL-20002 (Life Laboratory Company, Yamagata, Japan),
according to the manufacturer’s instructions. Results were corrected
for cell number, respectively. Cell number was assessed using
tetrazolium salt WST-1 (Dojindo Laboratories, Kumamoto, Japan),
according to the manufacturer’s instructions. Data are presented as
the relative values.
Direct effects of megsin on MMP activities
Cell-free direct assay was performed as below: 5 mU of included
standard MMP-9 protein was incubated with or without 10 mg of
recombinant megsin protein, and its activity was measured by the
LL-20002 kit (Life Laboratory Company) as above (n¼ 4). Data are
presented as relative values.
Development of anti-megsin monoclonal antibody
Male BALB/c mice (Charles River Japan, Kanagawa, Japan) were
immunized by recombinant human megsin protein. Hybridomas
expressing neutralizing antibodies were generated by a combined
polyethylene glycol electrofusion of spleen cells from immunized
mice and SP2 myeloma cells. They were screened by enzyme-linked
immunosorbent assay on plates coated with human megsin protein.
After incubation with each antibody, the wells were incubated
with horseradish peroxidase-conjugated anti-mouse IgG antibody
(Chemicon Inc., Temecula, CA, USA). For the development, the
wells were incubated with a reaction solution containing
o-phenylenediamine dihydrochloride, and absorbance was measured
at 490 nm. Positive hybridomas were subcloned by limiting dilution.
A clone named MS18a was eventually identified among these clones
for subsequent screening. Antibody isotyping showed that MS18a is
IgG1 molecule.
Epitope mapping
The anti-megsin monoclonal antibody MS18a was pre-incubated
with an excess of the several synthetic human megsin peptides
(Fuso Pharmaceutical Industries, Osaka, Japan) (Table 3) for 2 h.
They were subsequently evaluated by enzyme-linked immuno-
sorbent assay on plates coated with human megsin protein as above.
Validation of neutralizing activity of MS18a
For validation of neutralizing activity of MS18a, cell-free assay was
performed as below. A total of 4 mg of human megsin protein was
pre-incubated with 10 mg of control mouse IgG, 10mg of MS18a, or
10 mg of MS18a pre-incubated with an excess of the blocking peptide
corresponding to the reactive loop site of rat megsin, that is,
TAATESNIVEKLLPES (Sigma-Aldrich). They were subsequently
incubated with 250 ng of plasmin (Sigma-Aldrich) for 30 min
(n¼ 3). The wells were incubated with S-2403 substrate, and
absorbance was measured at 405 nm. Data are presented as relative
values.
Neutralization of megsin in RMCs
RMCs were cultured in 96-well plates and grown to subconfluence.
They were subsequently washed and incubated with DMEM (5 or
25 mM D-glucose with 10% fetal bovine serum) containing either
100 mg/ml MS18a or control mouse IgG for 72 h (n¼ 8). After
incubation, the culture supernatant was collected for the measure-
ment of the total MMP-2 and MMP-9 activities by the LL-20002 kit
(Life Laboratory Company) as above. Data are presented as relative
values.
Direct interrelation between MS18a and MMP activities
Cell-free direct assay was performed as below: 5 mU of included
standard MMP-9 protein was incubated with or without 10 mg of
anti-megsin monoclonal antibody MS18a, and its activity was
measured by the LL-20002 kit (Life Laboratory Company) as above
(n¼ 4). Data are presented as relative values.
Effects of megsin and TGF-b on genes expressions
RMCs were cultured in 96-well plates and grown to confluence.
They were subsequently washed and incubated with serum-starved
DMEM (5 mM D-glucose) containing TGF-b (5 ng/ml, Sigma-
Aldrich) or megsin (100 ng/ml) for 24 h (n¼ 6). Total RNA was
isolated from RMCs with the RNeasy Mini Kit, and mRNA
expression was evaluated by real-time PCR.
Effects of megsin on PAI-1 activity
Cell-free direct assay was performed as below. The PAI-1 activity was
determined by a commercially available kit (HYPHEN BioMed,
Neuville-sur-Oise, France). A total of 1 ng of included standard
PAI-1 protein was incubated with or without 25 ng of recombinant
megsin protein, and its activity was measured according to the
manufacturer’s instructions (n¼ 4). Data are presented as the
relative values.
Statistical analysis
All data are reported as the mean±s.e.m. Statistical analysis was
performed with SPSS for Windows version 15.0 (SPSS, Chicago, IL,
USA). Comparisons between two groups were performed using an
unpaired t-test. For multiple comparisons, one-way analysis of
variance and Tukey’s post hoc test were performed. Po0.05 was
considered significant.
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